+ Follow SIMVASTATIN Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1338997
[Title] => Mataas ang cholesterol
[Summary] => NAPAKARAMING pasyenteng mahihirap ang nareresetahan ng mamahaling gamot sa cholesterol. Ang tawag dito ay Statins at nagkakahalaga ito ng P20–P60 bawat tableta. Ang mga kilalang Statins ay ang Simvastatin, Atorvastatin, at iba pa.
[DatePublished] => 2014-06-26 00:00:00
[ColumnID] => 134020
[Focus] => 0
[AuthorID] => 1805275
[AuthorName] => Dr. Willie T. Ong
[SectionName] => PSN Opinyon
[SectionUrl] => opinyon
[URL] =>
)
[1] => Array
(
[ArticleID] => 1321682
[Title] => The age of statins
[Summary] => It has been 17 years since the first publication of the Scandinavian Simvastatin Survival Study (Lancer ‘1994;344; 1383-9) describing the benefit of coenzyme A reductase inhibitors (statins) on cardiovascular events in patients with coronary heart disease.
[DatePublished] => 2014-05-11 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[2] => Array
(
[ArticleID] => 1157431
[Title] => Simvastatin label now discourages higher dose
[Summary] => A recommendation against prescribing the highest available dose of simvastatin is among the changes in the labeling information for the drug, the Food and Drug Administration announced.
[DatePublished] => 2013-09-01 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[3] => Array
(
[ArticleID] => 945224
[Title] => BOC seizes P25-M fake drugs from South Korea
[Summary] => The Bureau of Customs (BOC) yesterday seized P25 million worth of fake and expired medicine that allegedly came from South Korea.
[DatePublished] => 2013-05-23 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] => 1096905
[AuthorName] => Evelyn Macairan
[SectionName] => Metro
[SectionUrl] => metro
[URL] =>
)
[4] => Array
(
[ArticleID] => 663193
[Title] => FDA review backs ezetimibe and simvastatin combination
[Summary] => After a year-long review of data from the ENHANCE trial that showed no significant difference in the changes in carotid artery thickness between patients treated with ezetimibe and simvastatin, vs. simvastatin alone, the Food and Drug Administration has concluded that patients should not stop taking ezetimibe/simvastatin or any cholesterol-lowering medications.
[DatePublished] => 2011-03-06 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[5] => Array
(
[ArticleID] => 636431
[Title] => Hearty news from MSD
[Summary] => A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo (p=0.0010).
[DatePublished] => 2010-12-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[6] => Array
(
[ArticleID] => 46972
[Title] => Famous drugs I have never prescribed
[Summary] =>
[DatePublished] => 2008-02-26 00:00:00
[ColumnID] => 134789
[Focus] => 0
[AuthorID] => 1805275
[AuthorName] => Dr. Willie T. Ong
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[7] => Array
(
[ArticleID] => 269153
[Title] => Cholesterol goal lowered for high-risk patients
[Summary] => Until recently, the goal for all people was to have LDL – "bad" cholesterol – levels below 100. Heart experts now believe that those at high-risk for a heart attack or those who have recently had a heart attack should try to lower their LDL cholesterol levels to below 70. The recommendation came from a panel of doctors from the National Institutes of Health’s National Cholesterol Education Program. The panel reviewed several recent clinical trials on the benefits of further lowering LDL cholesterol.
[DatePublished] => 2005-03-06 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[8] => Array
(
[ArticleID] => 269277
[Title] => Cholesterol goal lowered for high-risk patients
[Summary] => Until recently, the goal for all people was to have LDL – "bad" cholesterol – levels below 100. Heart experts now believe that those at high-risk for a heart attack or those who have recently had a heart attack should try to lower their LDL cholesterol levels to below 70. The recommendation came from a panel of doctors from the National Institutes of Health’s National Cholesterol Education Program. The panel reviewed several recent clinical trials on the benefits of further lowering LDL cholesterol.
[DatePublished] => 2005-03-06 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[9] => Array
(
[ArticleID] => 243009
[Title] => Criteria for the appropriate statin cited
[Summary] => Doctors have always been quick to prescribe statins to their patients with lipid abnormalities. A medicine which is known to significantly lower cholesterol level, statin has gained its place in the doctors‚ therapeutic armamentarium for the treatment of cholesterol and lowering the risk of cardiovascular complications such as heart attacks or strokes.
With its efficacy established, the market has been flooded with several brands of statins. A dilemma, however, arose since doctors and patients get more confused which brand to prescribe and take.
[DatePublished] => 2004-03-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
SIMVASTATIN
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1338997
[Title] => Mataas ang cholesterol
[Summary] => NAPAKARAMING pasyenteng mahihirap ang nareresetahan ng mamahaling gamot sa cholesterol. Ang tawag dito ay Statins at nagkakahalaga ito ng P20–P60 bawat tableta. Ang mga kilalang Statins ay ang Simvastatin, Atorvastatin, at iba pa.
[DatePublished] => 2014-06-26 00:00:00
[ColumnID] => 134020
[Focus] => 0
[AuthorID] => 1805275
[AuthorName] => Dr. Willie T. Ong
[SectionName] => PSN Opinyon
[SectionUrl] => opinyon
[URL] =>
)
[1] => Array
(
[ArticleID] => 1321682
[Title] => The age of statins
[Summary] => It has been 17 years since the first publication of the Scandinavian Simvastatin Survival Study (Lancer ‘1994;344; 1383-9) describing the benefit of coenzyme A reductase inhibitors (statins) on cardiovascular events in patients with coronary heart disease.
[DatePublished] => 2014-05-11 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[2] => Array
(
[ArticleID] => 1157431
[Title] => Simvastatin label now discourages higher dose
[Summary] => A recommendation against prescribing the highest available dose of simvastatin is among the changes in the labeling information for the drug, the Food and Drug Administration announced.
[DatePublished] => 2013-09-01 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[3] => Array
(
[ArticleID] => 945224
[Title] => BOC seizes P25-M fake drugs from South Korea
[Summary] => The Bureau of Customs (BOC) yesterday seized P25 million worth of fake and expired medicine that allegedly came from South Korea.
[DatePublished] => 2013-05-23 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] => 1096905
[AuthorName] => Evelyn Macairan
[SectionName] => Metro
[SectionUrl] => metro
[URL] =>
)
[4] => Array
(
[ArticleID] => 663193
[Title] => FDA review backs ezetimibe and simvastatin combination
[Summary] => After a year-long review of data from the ENHANCE trial that showed no significant difference in the changes in carotid artery thickness between patients treated with ezetimibe and simvastatin, vs. simvastatin alone, the Food and Drug Administration has concluded that patients should not stop taking ezetimibe/simvastatin or any cholesterol-lowering medications.
[DatePublished] => 2011-03-06 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[5] => Array
(
[ArticleID] => 636431
[Title] => Hearty news from MSD
[Summary] => A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo (p=0.0010).
[DatePublished] => 2010-12-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[6] => Array
(
[ArticleID] => 46972
[Title] => Famous drugs I have never prescribed
[Summary] =>
[DatePublished] => 2008-02-26 00:00:00
[ColumnID] => 134789
[Focus] => 0
[AuthorID] => 1805275
[AuthorName] => Dr. Willie T. Ong
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[7] => Array
(
[ArticleID] => 269153
[Title] => Cholesterol goal lowered for high-risk patients
[Summary] => Until recently, the goal for all people was to have LDL – "bad" cholesterol – levels below 100. Heart experts now believe that those at high-risk for a heart attack or those who have recently had a heart attack should try to lower their LDL cholesterol levels to below 70. The recommendation came from a panel of doctors from the National Institutes of Health’s National Cholesterol Education Program. The panel reviewed several recent clinical trials on the benefits of further lowering LDL cholesterol.
[DatePublished] => 2005-03-06 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[8] => Array
(
[ArticleID] => 269277
[Title] => Cholesterol goal lowered for high-risk patients
[Summary] => Until recently, the goal for all people was to have LDL – "bad" cholesterol – levels below 100. Heart experts now believe that those at high-risk for a heart attack or those who have recently had a heart attack should try to lower their LDL cholesterol levels to below 70. The recommendation came from a panel of doctors from the National Institutes of Health’s National Cholesterol Education Program. The panel reviewed several recent clinical trials on the benefits of further lowering LDL cholesterol.
[DatePublished] => 2005-03-06 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[9] => Array
(
[ArticleID] => 243009
[Title] => Criteria for the appropriate statin cited
[Summary] => Doctors have always been quick to prescribe statins to their patients with lipid abnormalities. A medicine which is known to significantly lower cholesterol level, statin has gained its place in the doctors‚ therapeutic armamentarium for the treatment of cholesterol and lowering the risk of cardiovascular complications such as heart attacks or strokes.
With its efficacy established, the market has been flooded with several brands of statins. A dilemma, however, arose since doctors and patients get more confused which brand to prescribe and take.
[DatePublished] => 2004-03-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
December 7, 2010 - 12:00am
